Dear Reader,

On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said:

"The dollar is going to hell."

The man who defended the US dollar for 60 years just told you it's done.

Ray Dalio agrees.

Source: International Business Times

The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral."

$38.4 trillion in debt.

Adding a trillion every 60 days. A billion every 8 hours.

The math doesn't work anymore.

If the dollar falls, most people will get hurt badly.

But there's a specific asset class and investment system that actually thrives when the dollar collapses.

It's called the ABN System.

It adapts the principles of Blackrock's investing strategy so everyday investors can apply it to protect themselves.

Over 4,500 members have already implemented this system.

If you have $50k+ exposed to the dollar right now (including your 401(k), stocks, real estate, savings), you need to pay attention.

Watch how to protect yourself from what Dalio and Buffett see coming (free training) ->

To your freedom,
Tan Gera, CFA©
Decentralized Masters

P.S. JPMorgan warned we're at 120% debt-to-GDP. Greece collapsed at 130%. Watch the presentation now.

2 Biotech Stocks Shaping Up for Major Breakouts

Reported by Ryan Hasson. Article Posted: 8/22/2026.

The biotech sector just received the kind of catalyst that can define a cycle. On Wednesday, Moderna (NASDAQ: MRNA) stunned the market when its personalized mRNA cancer vaccine, developed with Merck (NYSE: MRK), became the first such therapy to succeed in a late-stage trial, reducing the risk of melanoma recurrence.

The stock closed up an astonishing 177%, and the implications extend far beyond a single company. The results represent a landmark validation of the broader mRNA platform and a potential turning point for cancer treatment itself.

The news landed as the sector was already surging. The iShares Biotechnology ETF (NASDAQ: IBB) is up about 25% year to date, with much of that growth coming in the last 30 days. During that period, the ETF hit a fresh 52-week high, demonstrating the kind of strength that tends to draw new money off the sidelines. With Moderna's breakthrough adding fuel to that momentum, biotech's leadership may strengthen further.

Two biotech names that have quietly built powerful uptrends throughout this run and now look poised to break out are Eli Lilly (NYSE: LLY) and Natera (NASDAQ: NTRA).

Eli Lilly: The Pharma Giant Still Dominating Its Market

Eli Lilly is the world's largest pharmaceutical company by market capitalization, a $1.2 trillion healthcare titan anchored by its blockbuster GLP-1 franchise. Even at that scale, the stock continues to climb, rising more than 15% year to date and jumping about 4% on Wednesday alone to close just below its 52-week high.

The freshest catalyst is Lilly's push into oral GLP-1 medications, a next-generation format that could significantly expand the weight-loss and diabetes markets beyond today's injectables and open the door to hundreds of millions of new patients.

That opportunity builds on an already dominant foundation, as Lilly's existing treatments continue to outpace rival Novo Nordisk (NYSE: NVO) in sales growth. A company this size rarely has both entrenched market leadership and a genuine new growth avenue, but Lilly has both.

On the analyst front, Lilly carries a Moderate Buy consensus across 30 analysts, while its news sentiment score ranks among the strongest in large-cap healthcare. The stock hit a new 52-week high on Wednesday, breaking above a resistance level that had held for nearly three months. If the stock can hold above $1,250, a major prior resistance level, a breakout on a significantly higher time frame could be in the cards for this sector-leading giant.

Natera: The Genetic Testing Leader Firing on All Cylinders

Natera offers a very different profile: It is a fast-growing diagnostics innovator specializing in cell-free DNA testing across reproductive health, oncology and organ transplantation. Its Signatera cancer-monitoring assay has become a standout product, and the company sits directly in the path of the precision-medicine wave sweeping through healthcare.

Natera has soared more than 40% year to date, easily outpacing the sector benchmark. Since breaking out of its multimonth base in June, the stock has continued its powerful advance, driven by accelerating revenue growth. Annual sales now top $2.3 billion.

The market is treating Natera as a genuine leader in its niche, and its status as a top-10 holding in the IBB underscores that standing.

Analysts remain constructive, with a Moderate Buy consensus from 22 analysts. Just last week, Citi reiterated a Buy rating on the stock and raised its price target from $315 to $365.

The one factor worth flagging is valuation. After such a run, Natera trades at a rich multiple of more than 20 times sales, making it a momentum-driven growth name rather than a value play. From a momentum perspective, the chart is also shaping up for another potential breakout. Following its recent earnings, the stock has spent several weeks consolidating near its 52-week highs and building a tight base. If NTRA pushes through its 52-week high, it could signal a breakout, with further upward momentum potentially following as the uptrend expands.

2 Leaders at a Pivotal Moment

What makes these two names compelling right now is the timing. Both have already demonstrated strength through months of outperformance, and both enter this moment with sectorwide momentum at their backs following Moderna's historic breakthrough. Eli Lilly offers scale, dominance and a fresh oral-drug catalyst, while Natera brings explosive growth and leadership in precision diagnostics. With biotech breaking out as a group and these two stocks pressing against their highs, the setup is worth watching closely. As always, the charts will tell the final story, but the fundamental and sector backdrop could hardly be more supportive.

Dear Reader,

In a few short months, the US government could make a sweeping change to bank accounts nationwide.

It will give them unprecedented powers to control your bank account.

They could closely track every transaction... even freeze it.

Fortunately, there are 4 simple steps you can take today that could safeguard your savings.

Discover these 4 simple steps here.

Good luck and God bless!

Martin D. Weiss, PhD
Weiss Ratings Founder

3 Robotics Stocks Under $10: Value, Momentum, or Bet?

Authored by Chris Markoch. Article Published: 8/17/2026.

Robotics stocks have fallen sharply from their 2025 highs. That’s creating an opportunity to buy three stocks for under $10. A cheap stock isn't automatically an undervalued one. However, institutional investors frequently treat stocks under $10 differently from the rest of the market, even in an emerging field like robotics.

That creates an inefficiency that retail investors can exploit. But here’s the challenge: it’s tempting to lump all of these stocks together as one trade. In this case, that would be a mistake.

What separates a real opportunity from a value trap is the gap between the market’s perception of a business and what's really happening inside it. These three robotics stocks fell below $10 for completely different reasons. That distinction matters to investors making investment decisions.

For Mobileye Global (NASDAQ: MBLY), the sell-off looks like an established, profitable company getting punished for leadership uncertainty. Ondas (NASDAQ: ONDS) has a momentum story that's already run hard on real contract wins, raising the question of how much good news remains to be priced in. Palladyne AI (NASDAQ: PDYN) is a purely speculative bet, with the market yet to decide what the business is worth.

Mobileye: The Value-Versus-Sentiment Gap

Many stocks under $10 are story stocks. That's not the case with Mobileye. This is a real, profitable business with decades of driver-assist technology embedded in relationships with automakers worldwide. That's what makes its slide into single digits notable.

The stock took a hit after the Consumer Electronics Show (CES), as investors felt the company wasn't showing enough new commercial progress. It then dropped sharply again after founder and CEO Amnon Shashua announced plans to step down once a successor is found.

But here’s what should matter to investors: Mobileye’s fundamentals didn't deteriorate alongside the stock price. Its Q2 2026 earnings report showed adjusted operating profit up nearly 50% year-over-year, and management raised full-year guidance.

Mobileye also outlined plans to move beyond licensing technology and operate a robotaxi fleet in a major U.S. city by 2027. That would tie the company directly into the broader autonomy trade rather than leave it as just a chip supplier.

Analyst opinion is genuinely split. The consensus price target from 25 analysts is $12.64, a gain of over 40% from recent prices. However, price targets range widely. That split is the tell. When a stock's fundamentals improve while its price falls, the market isn't repricing the business. It's discounting uncertainty around leadership. That uncertainty will eventually resolve, one way or another, and the stock will likely follow.

Ondas: Momentum Meeting Its Own Success

Ondas has completed one of the more dramatic transformations in small-cap defense technology. The company has evolved from a niche wireless networking company into a real counter-drone and autonomous systems player.

Through acquisitions like Sentrycs and Cyberhawk, along with organic contract wins, the Ondas Autonomous Systems segment has posted strong year-over-year revenue growth, with margins climbing as the business mix shifts toward higher-value defense work.

There’s also been positive news on the new-contract front. Ondas closed the Cyberhawk deal, landed a stadium security contract with the Jacksonville Jaguars, picked up tens of millions of dollars in defense orders, and brought on a former head of Israeli intelligence to lead its defense unit.

Analyst sentiment has followed. The Ondas analyst forecasts on MarketBeat show that 10 analysts give the stock a consensus rating of Moderate Buy, with a $16.56 target, representing upside of over 80% from the stock price as of this writing.

The complication is that the stock has already made an enormous move over the trailing 12 months. In June 2026, the market pushed back on dilution concerns tied to the equity issued to fund the acquisition spree.

This is a case where perception and fundamentals have actually been running close together for a while, which is unusual for a stock this volatile. The risk is that much of the story may already be priced in.

Palladyne AI: The Market Hasn't Decided Yet

Palladyne AI is the purest AI bet of the three. Its Palladyne IQ platform sits on top of third-party hardware and is designed to enable robots to perceive and adapt to their environment in real time.

Like Ondas, Palladyne has landed several defense contracts, including an Air Force Research Laboratory award, a STRATFI contract that's grown into eight figures, and Army swarm-coordination work.

In the company’s Q2 2026 earnings report, revenue narrowly missed consensus estimates, as did the loss per share. That's not unusual for early-stage companies spending ahead of revenue.

Analyst coverage remains thin, so the consensus rating can swing sharply on individual updates, and the gap between the high and low price targets is wide. That spread tells you the Street hasn't reached a conviction about what this business is worth.

That's the defining trait of Palladyne compared to the other two names. Mobileye and Ondas both have market opinions that current fundamentals may be misjudged. Palladyne doesn't have a settled opinion yet. That makes it the highest-risk, highest-uncertainty name of the group and one that demands position sizing to match.